التفاصيل البيبلوغرافية
| العنوان: |
GLOFITAMAB PLUS POLATUZUMAB VEDOTIN DEMONSTRATES DURABLE RESPONSES AND A MANAGEABLE SAFETY PROFILE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA. |
| المؤلفون: |
Hutchings, M., Avigdor, A., Sureda, A., Terol, M. J., Bosch, F., Corradini, P., Larsen, T. Stauffer, Domínguez, A. Rueda, Skarbnik, A., Jørgensen, J., Goldschmidt, N., Gurion, R., Zinzani, P. L., Pinto, A., Cordoba, R., Bottos, A., Huang, Z., Simko, S., Relf, J., Filézac de L'Etang, A. |
| المصدر: |
Hematological Oncology; Jun2023 Supplement 1, Vol. 41, p138-140, 3p |
| مصطلحات موضوعية: |
DIFFUSE large B-cell lymphomas, PATIENT safety |
| مستخلص: |
GLOFITAMAB PLUS POLATUZUMAB VEDOTIN DEMONSTRATES DURABLE RESPONSES AND A MANAGEABLE SAFETY PROFILE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA B Introduction: b Glofitamab (Glofit) is a bispecific CD20:CD3 antibody which redirects T cells to eliminate malignant B cells. The CD79b targeted antibody-drug conjugate polatuzumab vedotin (Pola) is approved in combination with bendamustine and rituximab for the treatment of I R i / I R i DLBCL. [Extracted from the article] |
|
Copyright of Hematological Oncology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder